On Wednesday 6th November 2024, Ionis Pharmaceuticals (NASDAQ: IONS) will be releasing its third quarter financial results. This much awaited announcement will be made before market open.
the concern is expected to report an estimated per share $1.16 loss for the quarter, as predicted by financial analysts on Wall Street. Furthermore, the company is anticipated to disclose a total revenue of $129.88 million during this period.
Upon revisiting the corresponding quarter from the prior year, the company's earnings report demonstrated a per-share loss of $0.85. This figure was attributed to the company's total revenue, which reached an impressive $144 million during that same period.
Analysts forecasting the company's performance for this year have been made public. The estimated total revenue is about $623.94 million. They also predict that throughout the course of the fiscal year, the business will make about loss of $3.7 per share.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q1 2024 | $-0.77 | -13.2% | 119.00 M | -9.2% |
| Q4 2023 | $-0.06 | +94.9% | 325.00 M | +113.8% |
| Q3 2023 | $-0.85 | -431.3% | 144.00 M | -10.0% |
| Q2 2023 | $-0.41 | +26.8% | 188.00 M | +40.3% |
| *Growth on year-over-year basis | ||||
The business has scheduled a conference call on 6th November 2024 at 11:30 AM eastern time to discuss Q3 financial results.
Throughout Friday's trading, Ionis Pharmaceuticals (IONS) shares fluctuated between $38.19 and $39.02, with a trading volume of 739.60 thousand shares. The stock ended the regular trading session at $38.76, demonstrating a gain of 0.96 percent.
